Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENCEPT 10/11-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Female contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily CYP3A4; Levonorgestrel: CYP3A4, undergoes reduction and sulfation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
98% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Volume of distribution is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral bioavailability is approximately 90%, with minimal first-pass metabolism.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 m L/min), use with caution due to potential fluid retention and hypertension.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with Child-Pugh class B or C hepatic impairment (moderate to severe). In mild hepatic impairment (Child-Pugh class A), use with caution due to altered hormone metabolism.
No data available for fictional drug ALYACEN 777.
Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, follow same dosing as adults.
No data available for fictional drug ALYACEN 777.
Not indicated for use in women above 55 years of age due to increased risk of thromboembolic events and lack of efficacy data.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Visual abnormalities (retinal thrombosis, papilledema),Hepatic neoplasia (benign/malignant liver tumors),Hypertension,Glucose intolerance/diabetes,Gallbladder disease,Depression,Bleeding irregularities
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions are known. However, grapefruit juice may increase ethinyl estradiol levels; consider limiting grapefruit juice intake. Avoid excessive alcohol, as it may increase liver toxicity risk.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregnancy. First trimester: no increased risk of major birth defects based on epidemiological studies, but should not be used once pregnancy is confirmed. Second and third trimesters: no therapeutic indication; animal studies show fetotoxicity at high doses. Overall, use is not recommended in pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Gestodene and ethinylestradiol are excreted in breast milk in small amounts. The M/P ratio for ethinylestradiol is approximately 0.02; for gestodene, it is unknown but likely low. Combined hormonal contraceptives may reduce milk production and composition, especially in early lactation; use is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only alternatives are preferred.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) would theoretically reduce ethinylestradiol and gestodene levels, but since the drug is not used in pregnancy, no dosing recommendations are made.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
GENCEPT 10/11-28 is a combination oral contraceptive containing ethinyl estradiol 10 mcg and drospirenone 3 mg (24 active tablets) plus placebo (4 tablets). It is used for contraception and treatment of moderate acne vulgaris in women who desire oral contraception. The 24-day active regimen increases ovarian suppression and reduces breakthrough bleeding. Drospirenone has antimineralocorticoid activity, which may cause hyperkalemia in patients with renal impairment, hepatic disease, or adrenal insufficiency. Monitor potassium in at-risk patients. Do not use with other potassium-sparing drugs. Avoid in women with hypertension, diabetes with vascular disease, or migraine with aura due to increased cardiovascular risk with low-dose EE. Consider starting on first day of menses for immediate contraceptive effect.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, in the order shown on the pack. Do not skip pills.,Use backup contraception (e.g., condoms) if you miss a pill, vomit within 3-4 hours after taking a pill, or have severe diarrhea.,Contact your doctor immediately if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Cigarette smoking increases the risk of serious cardiovascular side effects. Do not smoke while taking this medication.,Store at room temperature, away from moisture and heat.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENCEPT 10/11-28 vs ALYACEN 777, answered by our medical review team.
GENCEPT 10/11-28 is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENCEPT 10/11-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENCEPT 10/11-28 is: One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENCEPT 10/11-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENCEPT 10/11-28 is classified as Category C. GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregn. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.